2025Year11Month18Day，Medical Technology CompanyVahatiCorAnnouncement Completed2300Million USDBRound of financing, byS3 VenturesLeading the investment,Intuitive Venturesand strategic investors' follow-on investment. This round of financing will mainly be used to advance its core products.A-FLUXFlow Reduction System®OfSERRA-IEarly feasibility studies, and accelerate engineering development and subsequent key trial preparations.

Coronary Microvascular Dysfunction (CMD) is a public health issue with strong concealment and significant harm. According to industry data, the United States alone has300Ten Thousand-400Hundreds of Thousands of Patients Affected by This Condition – Despite No Obstructions in the Main Coronary Arteries, Patients Repeatedly Experience Symptoms Such as Chest Pain and Angina. The Female Population is Particularly at High Risk, with a Higher Risk of Cardiac Events Than Men When Coronary Blood Flow is Impaired.2-4Times. The current medical community is facing a severe treatment dilemma: exceeding50%Patients do not respond to existing anti-anginal drugs, and the lack of therapies that directly improve coronary blood flow reserve leads to repeated hospitalizations, high medical costs, and delayed diagnosis further exacerbates the psychological burden.

VahatiCorSolutionA-FLUXFlow Reduction System®Is the world's first targetedCMDInstrument therapy.This coronary sinus reduction device optimizes oxygenated blood flow distribution through controlled stenosis technology, enhances myocardial perfusion, and alleviates angina symptoms. Its core innovation lies in the repositionable, self-expanding engineering design, achieving a breakthrough improvement in surgical safety and efficacy.

It is worth mentioning that the main investors this time includeIntuitive Ventures。Giant of Surgical RobotsIntuitive Surgical（Intuitive Surgical）2020Year10First launched in [Month]1The establishment of a billion-dollar venture capital fund.2023Year,Intuitive VenturesCompleted1.5 Billion US dollarsIIThe establishment of the fund,Intuitive VenturesThe scale of managed funds has thus grown to2.5 Hundreds of millions of dollars, continuing to invest in innovative minimally invasive diagnosis and treatment startups.

According toIntuitive VenturesThe announcement shows,Intuitive Ventures Since its establishment, it has invested in10 Multiple transformative startups, which have gained exciting momentum and created value throughout the diagnosis and treatment process. Their global investment focus covers diagnostics, medical technology, innovative therapies, and digital health.UtilizeIntuitiveThe unique advantages can accelerateIntuitive VenturesImpact of Portfolio Companies.

Intuitive VenturesSenior PartnerTerri BurkeEmphasized: "VahatiCorPatient-centered innovation precisely addresses unmet needs such as recurrent angina and declining quality of life, with a clear clinical pathway that holds promise to revolutionize minimally invasive treatment paradigms.

VahatiCorYesT45 LabsA medical technology company under the group that focuses on the transformation of cardiac care, concentrating on solving coronary microvascular dysfunction (CMD) This long-neglected public health challenge.VahatiCorCore ProductA-FLUX ReducerThe system is the world's first targetingCMDMinimally invasive self-expanding stent,The hourglass-shaped design is made by weaving nickel-titanium alloy.SwiftCellThree Major Innovations in Technical Implementation:

• Variable Cell Structure: Immediately redistributes cardiac blood flow post-implantation, optimizing oxygenated blood distribution;

  
  

• Hourglass Shape Adaptability: Narrow in the middle and wide at both ends design adapts to different physiological anatomical structures, combined with shape memory materials for seamless fitting to the coronary sinus, ensuring long-term clinical outcomes;

  
  

• Operational Advantages: Repositionable and self-expanding features enhance surgical safety.Different from Johnson & JohnsonShockwave Reducer(The rigid expansion method (made of stainless steel and requiring balloon expansion) is more in line with the physiological characteristics of the coronary sinus.)

  
  

VahatiCorLaunchedSERRA-IEarly Feasibility Study, Coverage6Research Center,30Example subjects, key assessmentsA-FLUXIn persistent symptomsCMDSafety and preliminary efficacy in patients. This study lays the foundation for subsequent pivotal trials and regulatory submissions.Preclinical Data and Johnson & JohnsonShockwave ReducerOfREDUCER-IResearch (3Years of continuous improvement in angina symptoms and quality of life) form a呼应, butVahatiCorThe nitinol material and self-expanding design demonstrate differentiated advantages in blood flow redistribution efficiency and surgical operability.

Compared to Johnson & JohnsonShockwave ReducerThe stainless steel material and balloon expansion requirements,A-FLUXThe nickel-titanium alloy self-expanding design demonstrates unique value in biocompatibility, surgical safety, and blood flow optimization efficiency, making it particularly suitable for patient populations with varied coronary sinus morphology. This design differenceVahatiCorInCMDCompanies that gain a technological edge in the medical device sector have become key targets for capital investment as innovative enterprises.

The oversubscription of this financing roundIntuitive VenturesEndorsement, further consolidatedVahatiCorInCMDLeadership in the field of treatment,Instrument之家 will continue to follow the company's next steps.